BioTelemetry Research and AMRA Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials
October 25 2017 - 8:30AM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, announced that
BioTelemetry Research, their leading global imaging and cardiac
core lab, and AMRA, the international leader in body composition
analysis, have formed an exclusive alliance for non-alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
clinical trials. This first-to-market partnership will advance
imaging science and benefit clinical trial sponsors in several
musculoskeletal and metabolic therapeutic areas.
In clinical studies, muscle and fat fractions have traditionally
been measured by scanning individual organs such as the liver, or
particular body regions such as the abdomen. Commonly, researchers
would prefer to scan the entire body in order to learn exactly
where study participants are losing or gaining muscle or fat mass.
However, until now they have been constrained by prohibitive costs
and insufficiently precise outcomes.
AMRA’s body composition analysis service has introduced a new
and better paradigm where rapid, six-minute whole body MRI scans
are transformed into precise, three dimensional-volumetric fat and
muscle measurements. This standardized, automated method eliminates
reader variability and reduces processing costs. With those
advancements, BioTelemetry Research is able to provide clinical
trial sponsors with new, high-value information about their drug
compounds’ efficacy and mechanisms of action, including the
identification of previously undetectable changes within and beyond
the liver.
Tommy Johansson, Chief Executive Officer of AMRA, commented,
“BioTelemetry Research is the ideal core lab to help us deliver
this enhanced value to clinical trial sponsors. They bring unique
expertise managing the protocol complexity, site training intensity
and equipment variability that are common to non-standard-of-care
MRI trials.” He continued, “BioTelemetry was a leading pioneer in
proton density fat fraction (PDFF) analysis, and have analysed more
liver fat cases, from more sites, in more regions than any other
group in industry. I am excited to see where our partnership will
take us.”
BioTelemetry Research President and General Manager, Scott
Satin, added, “By employing AMRA’s automated analysis, we are now
able to efficiently provide more actionable data to our
pharmaceutical partners. Ordinarily, a whole body MRI scan takes 10
to 15 minutes and produces hundreds of images. Prior to AMRA, such
analyses were infeasible in clinical trials largely because of the
time needed to label fat and muscle tissues within every image.
With those challenges eliminated, we can now help sponsors assess
the effects of their treatments more quickly and completely.”
Through collaboration with leading universities such as the
University of California, San Diego (UCSD) and the University of
Westminster, London, AMRA’s technique has been proven to enable
market-leading accuracy and precision when measuring fat depots and
muscle volumes, as well as the fat infiltration of muscles and in
organs. BioTelemetry has the scientific expertise and operational
experience to apply this technique successfully in global clinical
trials. Together, the alliance is committed to accelerate the
prevention and treatment of diseases such as NAFLD and obesity.
About BioTelemetry
BioTelemetry Research is the clinical research division of
BioTelemetry, Inc., (NASDAQ:BEAT) the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care. The Company
currently provides cardiac monitoring services, original equipment
manufacturing with a primary focus on cardiac monitoring devices
and centralized imaging and cardiac core laboratory
services. More information can be found at
www.gobio.com/research.
About AMRA
AMRA is the first in the world to transform images from a rapid,
6-minute whole body MRI scan into precise, 3D-volumetric fat and
muscle measurements. AMRA’s cloud-based analysis service offers
precise, automated insights that have far-reaching implications for
the pharmaceutical industry, academic R&D and, soon, clinical
practice. AMRA was founded in 2010 as a spin-off of the Center for
Medical Image Science and Visualization (CMIV), the Department of
Biomedical Engineering (IMT) and the Department of Medicine and
Health (IMH) at Linköping University, Sweden. For more information,
visit www.amra.se.
Cautionary Statement Regarding Forward-Looking
Statements This document includes certain
forward-looking statements within the meaning of the “Safe Harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as “expect,”
“anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises”
and other words and terms of similar meaning. Such forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties, including important factors that could
delay, divert, or change any of these expectations, and could cause
actual outcomes and results to differ materially from current
expectations. These factors include, among other things, effects of
changes in health care legislation, effectiveness of our cost
savings initiatives, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive
management and sales personnel, our ability to identify acquisition
candidates, acquire them on attractive terms and integrate their
operations into our business, the commercialization of new
products, market factors, internal research and development
initiatives, partnered research and development initiatives,
competitive product development, changes in governmental
regulations and legislation, the continued consolidation of payors,
acceptance of our new products and services, patent protection,
adverse regulatory action, litigation success, our ability to
successfully create a new holding company structure and to
anticipate the benefits of such structure. For further details and
a discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange
Commission, including our latest periodic reports on Form 10-K and
10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
BioTelemetry, Inc.Heather C. GetzInvestor
Relations800-908-7103InvestorRelations@biotelinc.com
Advanced MR Analytics ABChelsea RangerSVP
Business Developmentchelsea.ranger@amra.se
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024